SCOR (SCR) AGM 2025 summary

Opening remarks and agenda

• The meeting opened with a welcome to shareholders, board members, and journalists, emphasizing teamwork and transparency in 2024.

• The constitution of the bureau was established, with scrutineers and a secretary appointed, and the meeting was declared open with a quorum of 72.47% of shares represented.

• Legal documents, agenda, draft resolutions, and reports were made available to shareholders in advance.

• The meeting was chaired by the board president and CEO, focusing on 2024 performance and strategic direction for 2025-2026.

Financial performance review

• 2024 results showed resilience, with a robust solvency ratio of 210% and strong technical and financial contributions.

• Life & Health suffered a EUR 350 million loss due to reserve reviews, but actions were launched to restore profitability.

• Adjusted return on equity reached 14.9% after exceptional items; economic value grew 9.8% on the same basis.

• The P&C business performed excellently, with a ratio below 87%, and investments yielded stable, positive returns.

Board and executive committee updates

• Succession planning for board, executive committee, and committee chairs was a key focus.

• Board composition remains diverse: 14 directors, 50% women, over 80% independence, 9 nationalities.

• Three board mandates proposed for renewal; two new independent directors and one new censeur introduced.

• The nominations and compensation committees were merged, and new members were assigned to key committees.